Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.
Qian Qin(Icahn School of Medicine at Mount Sinai), Che‐Kai Tsao(Mount Sinai Hospital), Xiaobo Zhong(Icahn School of Medicine at Mount Sinai), Amanda Leiter(Icahn School of Medicine at Mount Sinai), Mahalya Gogerly-Moragoda(Icahn School of Medicine at Mount Sinai), Matt D. Galsky(University of California, San Francisco), Emily J. Gallagher(Icahn School of Medicine at Mount Sinai), Vaibhav G. Patel(Arvinas (United States)), William Oh(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Anish B. Parikh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Bo Wang(Icahn School of Medicine at Mount Sinai), George Mellgard(Memorial Sloan Kettering Cancer Center)
Cited by 16
Related Papers
Whole-Body Hypothermia for Neonates with Hypoxic–Ischemic Encephalopathy
|New England Journal of Medicine|2005|2.8k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Late-Onset Sepsis in Very Low Birth Weight Neonates: The Experience of the NICHD Neonatal Research Network
|PEDIATRICS|2002|2.4k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k